The effects of bolus infusion versus continuous injection of doxorubicin in children with A
Phase 3
Recruiting
- Conditions
- Acute lymphoblastic leukemia.Acute lymphoblastic leukemia not having achieved remissionC91.00
- Registration Number
- IRCT20180209038673N7
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Normal echocardiography,
Written consent from parents,
patients under 18 years of age,
patients with ALL who usd doxorubicin in their drug regimen
Exclusion Criteria
Previous history of chemotherapy or radiation therapy
Diagnosis of congenital heart disease
Diagnosis of heart failure
Diagnosis of kidney failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiotoxicity effect. Timepoint: 6 months after treatment. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method WBC measurement. Timepoint: 6 months after therapy. Method of measurement: CBC instrument.